Rafael J Tamargo

Title: Rafael J Tamargo: Innovator in Angiogenesis Inhibition

Introduction

Rafael J Tamargo is a notable inventor based in Baltimore, MD (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions aimed at inhibiting angiogenesis. His innovative work has the potential to impact various medical treatments.

Latest Patents

Rafael J Tamargo holds a patent for an antibiotic composition designed for the inhibition of angiogenesis. This pharmaceutical composition delivers an effective dose of an angiogenesis inhibitor, which consists of a tetracycline or a tetracycline derivative such as minocycline. The effective dosage for inhibiting angiogenesis, based on in vitro testing, ranges from one to 500 micromolar. The compositions can be delivered topically, locally, or systemically through implants or injections. Notably, this composition is extremely selective for the growth of endothelial cells, inhibiting their growth without being cytotoxic at effective dosages. He has 1 patent to his name.

Career Highlights

Throughout his career, Rafael J Tamargo has focused on advancing medical science through innovative research and development. His work has garnered attention for its potential applications in treating various conditions related to abnormal blood vessel growth.

Collaborations

Rafael has collaborated with esteemed colleagues such as Henry Brem and Robert A Bok, contributing to a rich exchange of ideas and advancements in their respective fields.

Conclusion

Rafael J Tamargo's contributions to the field of angiogenesis inhibition highlight his role as an influential inventor. His innovative patent demonstrates the potential for significant advancements in pharmaceutical compositions aimed at improving patient outcomes.